Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer

Shields, Morgan C.; Chen, Kevin; Dutcher, Giselle; Patel, Ishika; Pellini, Bruna

doi:10.3390/ijms23169006

Cited by 23 publications

(9 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since our group and other researchers demonstrated that the detection and quantification of methylated ctDNA is a useful approach for therapy monitoring in lung cancer patients [ 14 , 15 , 16 ], more papers on this subject were published [ 20 , 21 ]. Moreover, the incorporation of liquid profiling as an additional clinical tool for the diagnosis, treatment stratification, detection of resistance mechanisms, and prognostic indication in lung cancer patients has been shown [ 22 , 23 , 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients

et al. 2023

View full text Add to dashboard Cite

Notwithstanding some improvement in the earlier detection of patients with lung cancer, most of them still present with a late-stage disease at the time of diagnosis. Next to the most frequently utilized factors affecting the prognosis of lung cancer patients (stage, performance, and age), the recent application of biomarkers obtained by liquid profiling has gained more acceptance. In our study, we aimed to answer these questions: (i) Is the quantification of free-circulating methylated PTGER4 and SHOX2 plasma DNA a useful method for therapy monitoring, and is this also possible for patients treated with different therapy regimens? (ii) Is this approach possible when blood-drawing tubes, which allow for a delayed processing of blood samples, are utilized? Baseline values for mPTGER4 and mSHOX2 do not allow for clear discrimination between different response groups. In contrast, the combination of the methylation values for both genes shows a clear difference between responders vs. non-responders at the time of re-staging. Furthermore, blood drawing into tubes stabilizing the sample allows researchers more flexibility.

show abstract

Section: Discussionmentioning

confidence: 99%

Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Moreover, cancer progression will also affect the ctDNA/cfDNA ratio [45,72]. At the step of sample preparation, it is important to centrifuge blood as soon as possible after collection to lower the risk of DNA contamination caused by cell lysis [73]. Various protocols suggest proceeding with centrifugation at different temperatures and speed conditions, depending on laboratory equipment; however, in general, centrifugation for 10 min at 1000-2000× g using a refrigerated centrifuge allows obtaining high-quality plasma, while centrifugation for 15 min at 2000× g removes platelets from the plasma [74].…”

Section: Variant Allele Frequency (Vaf)mentioning

confidence: 99%

Variant Allele Frequency Analysis of Circulating Tumor DNA as a Promising Tool in Assessing the Effectiveness of Treatment in Non-Small Cell Lung Carcinoma Patients

Galant,

Nicoś,

Kuźnar-Kamińska

et al. 2024

Cancers

View full text Add to dashboard Cite

Despite the different possible paths of treatment, lung cancer remains one of the leading causes of death in oncological patients. New tools guiding the therapeutic process are under scientific investigation, and one of the promising indicators of the effectiveness of therapy in patients with NSCLC is variant allele frequency (VAF) analysis. VAF is a metric characterized as the measurement of the specific variant allele proportion within a genomic locus, and it can be determined using methods based on NGS or PCR. It can be assessed using not only tissue samples but also ctDNA (circulating tumor DNA) isolated from liquid biopsy. The non-invasive characteristic of liquid biopsy enables a more frequent collection of material and increases the potential of VAF analysis in monitoring therapy. Several studies have been performed on patients with NSCLC to evaluate the possibility of VAF usage. The research carried out so far demonstrates that the evaluation of VAF dynamics may be useful in monitoring tumor progression, remission, and recurrence during or after treatment. Moreover, the use of VAF analysis appears to be beneficial in making treatment decisions. However, several issues require better understanding and standardization before VAF testing can be implemented in clinical practice. In this review, we discuss the difficulties in the application of ctDNA VAF analysis in clinical routine, discussing the diagnostic and methodological challenges in VAF measurement in liquid biopsy. We highlight the possible applications of VAF-based measurements that are under consideration in clinical trials in the monitoring of personalized treatments for patients with NSCLC.

show abstract

“…The predictive power of ccfDNA extends beyond cancer, holding promise in various other diseases where the monitoring of ccfDNA can aid in predicting disease flare-ups or relapse. This can be particularly valuable in managing chronic conditions, allowing for preemptive adjustments in treatment to mitigate the impact of a relapse or exacerbation [39].…”

Section: Predicting Disease Relapsementioning

confidence: 99%

Exploring the Role of Circulating Cell-Free DNA in Disease Diagnosis and Therapy

Odah

2024

Preprint

View full text Add to dashboard Cite

Recent advancements in molecular diagnostics have highlighted the potential of circulating cell-free DNA (ccfDNA) as a biomarker in various diseases. This study aims to explore the role of ccfDNA in the early diagnosis, prognosis, and therapeutic monitoring of diseases, with a focus on oncology. We conducted a comprehensive review and analysis of current literature, combined with experimental approaches involving advanced genomic sequencing and bioinformatics techniques. Our research systematically characterizes the molecular composition of ccfDNA, including its origins, size distribution, and methylation patterns, across different disease states. Furthermore, we investigate the dynamics of ccfDNA release and clearance in the bloodstream, elucidating mechanisms that could influence its diagnostic accuracy. In the context of cancer, we analyze the correlation between tumor-derived ccfDNA and disease progression, response to therapy, and overall survival. Our findings indicate that ccfDNA holds promise as a non-invasive biomarker for early disease detection, real-time monitoring of treatment efficacy, and potentially, predicting relapse. This study contributes to the growing field of liquid biopsies and opens new avenues for personalized medicine, emphasizing the need for standardized protocols in ccfDNA analysis to maximize its clinical utility. The implications of our findings extend beyond oncology, suggesting potential applications of ccfDNA in other pathological conditions.

show abstract

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer

Cited by 23 publications

References 129 publications

Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients

Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients

Variant Allele Frequency Analysis of Circulating Tumor DNA as a Promising Tool in Assessing the Effectiveness of Treatment in Non-Small Cell Lung Carcinoma Patients

Exploring the Role of Circulating Cell-Free DNA in Disease Diagnosis and Therapy

Contact Info

Product

Resources

About